

## Amniotics led consortium selected for EIC-Pathfinder grant of €3.8 million from the European Innovation Council

**Amniotics AB (publ) today announced it has been invited to finalise a grant agreement with the European Innovation Council (EIC) as part of a consortium set to receive a grant of €3,8 Million from the EIC Pathfinder programme. This grant will fund the development of iPS derived, enhanced Natural Killer (NK) cells by a consortium led by Amniotics AB. Other participants are Lund University, Medizinische Hochschule Hannover and the University of Copenhagen.**

Following the invitation Amniotics and the partners in the project will finalise the agreement with the EIC over the coming months. After agreement is signed, we expect to get the project started in Q1-2023 and it will continue for thirty-six months.

*“We are delighted to be selected to receive the EIC-Pathfinder grant, which will support our AMNI-NK003 project in a real and substantive way,” says Marcus Larsson M.D., Ph.D., Chief Executive Officer of Amniotics AB. “Today there is a great need for treatments for patients with cancer, and off shelf allogeneic NK-cells has the potential to become an important tool to fight hematological malignancies and solid tumours. The Amniotics team and its partners have put together a robust plan to further our drug development activities and the recognition of the EIC lends us the credibility our programme warrants”.*

The European Innovation Council (EIC) Pathfinder grants support research and consortia in investigating or developing emerging breakthrough technology to develop and scale-up game-changing innovations.

### **About AMNI-NK003**

Amniotics anti-cancer program AMNI-NK003 aims to generate off-the-shelf Natural Killer (NK) cells from induced pluripotent stem cells (iPS) targeting hematological and solid cancers. NK cell therapy is a therapeutic approach that uses immune cells to attack tumours. The difficulty of producing NK cells in large volumes has resulted in high production costs, which has hampered progress. AMNI-NK003 is designed to produce NK cells, with high anti-tumour efficacy, efficiently and on a large scale.

## For more information please contact

---

Marcus Larsson  
CEO, Amniotics AB  
Phone: +46 (0) 763 0840 91  
Email: [ml@amniotics.com](mailto:ml@amniotics.com)

or

Johny Humaloja  
CFO, Amniotics AB  
Phone: +46 (0) 735 0668 56  
Email: [jh@amniotics.com](mailto:jh@amniotics.com)

## About Amniotics

---

Amniotics is a biopharma company focusing on mesenchymal stem cells (MSC) from amniotic fluid. The company was born out of the discovery of a novel source of stem cells in full-term amniotic fluid. Based on a decade of research at the internationally recognized Lund University Stem Cell Centre and the Skåne University Hospital of Lund, the company is pioneering the harvesting and propagation of tissue specific neonatal quality mesenchymal stem cells (MSC). These stem cells have unique properties for applications in regenerative medicine. Amniotics has also an, by Läkemedelsverket (Swedish MPA), approved Good Manufacturing Practice (GMP) facility to produce Advanced Therapy Medicinal Products (ATMPs). With the GMP facilities operational since 2020, Amniotics is now in clinical phase with the leading drug candidate PulmoStem™. The company is looking to establish strategic partnerships with researchers and companies that are interested in developing stem-cell-based therapies targeting diseases with high unmet needs.

Amniotics (publ) has its headquarter in Lund, Sweden.

The company is listed at Nasdaq First North Growth Market in Stockholm.

Amniotics Certified Adviser at First North is Redeye AB, e-post: [certifiedadviser@redeye.se](mailto:certifiedadviser@redeye.se).

Learn more at [www.amniotics.com](http://www.amniotics.com).

*This information is information that Amniotics is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2022-11-14 10:20 CET.*

## Attachments

---

Amniotics led consortium selected for EIC-Pathfinder grant of €3.8 million from the European Innovation Council